With major consolidation in Biomedical industry, there are fewer acquirers for startup exit. Under current economic climate and globalization landscpe, with constraints of funding resources and active M&A in recent years, what makes the best strategy for optimal outcome of product exit? In this talk, the speaker will provide overview of 2019 market trends in biomedical industry, and share her experience and insight for strategic alliance and seamless execution from product development to commercialization. The process of due diligence to deal closing and management of post deal partnership will be also discussed.
【Speaker】
Shuling Cheng, Ph.D. Chief Strategy Officer, Medeon
• 20+ year in biomedical industry. Strong in management, strategy, business development and commercialization of IVD and MedTech for minimally invasive surgery in cardiovascular, laparoscopy and urology area. Experienced in building IP strategy and portfolio, bringing product from proof of concept through clinical, GMP production and regulatory approval. Enjoy problem solving and finding creative solutions to challenges. Recent accomplishment includes leading the consummation of a corporate deal in cardiovascular closure device of $50M with Terumo (2018) and on-going management of the corporate partnership.
• Chief Strategy Officer, Medeon BioDesign, (EVP, GM, COO and VP of R&D; responsible for IP, Regulatory, Quality, Clinical affairs and corporate partnership. (2014-current)
• Founder and CSO for NeoDiagnostic Labs and OncoHealth, which developed the core technologies of HPV E6E7 biomarkers for cervical cancer. (2005-2014)
• Inventor/author of more than 30 patents and scientific publications, serving as a lead researcher within the Division of Diagnostics at ThermoFisher and DiscoveRx
• Education: B.S. from National Chung-Hsing University, PhD from University of Illinois at Urbana-Champaign (UIUC), and post-doctoral training in Pathology at UIUC and Hematology at Stanford University (1997)
About Medeon
Medeon Biodesign, Inc. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of medical equipment. The Company's main products include medical apparatus and instruments used in laparoscopic minimally invasive surgeries and cardiac catheter-related minimally invasive surgeries. The Company distributes its products in domestic market and to overseas markets.
【Time】
11/27 Wed. 18:40~21:00
【Venue】
Taiwan Tech Arena 3F
3F, 2, Sec. 4, Nanjing E. Rd., Songshan District, Taipei City
台北市松山區南京東路四段2號3樓（臺北小巨蛋三樓）
【Agenda】
18:30~19:00 Reception
19:10~19:30 Opening
19:30~20:30 Sharing: Shuling Cheng, Ph.D.
20:30~21:00 Mixer & Networking
【Organizer】
BE Accelerator, BE Capital
【Co-organizers】
Taiwan Tech Arena
